KPNA2 and UBR5

  • Number of citations of the paper that reports this interaction (PMID 12011095)
  • 19
  • Data Source:
  • HPRD (two hybrid)

KPNA2

UBR5

Gene Name karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ubiquitin protein ligase E3 component n-recognin 5
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 104 interactors: ACTN1 ACTN4 ANKIB1 AP2B1 APOBEC1 APP ARL4A ARL5A BRCA1 BTBD2 CASP2 CCDC107 CDA CDK5RAP3 CHD3 CHEK2 CORO1B CREB3L3 CREBBP CSE1L CSNK1A1 CUL4B DCTN2 DDIT3 EP300 EPB41 FEZ2 FN1 FTH1 GART GMCL1 GRB2 H1F0 HAP1 HMG20A HNRNPC HOMER2 HOMEZ HSPA4 IFT20 IMMT INO80E ITK JUN KLC4 KPNB1 KRT18 KRT40 KRT8 LAMB2 LEF1 LZTS2 MAGED1 MAGEH1 MDFI MLH1 MORC3 MVP MYC NECAB2 NFKBIB NMNAT1 NR3C1 NUP153 NUP50 NUP62 NUTM1 PAX5 PLAG1 PNMA5 PRKD3 PTMA RAG1 RAN RANBP2 RBM48 RBPMS RECQL RELA RELB RGL2 RILP RNMT SART3 SERTAD3 SGK1 SLC2A2 SPRY1 SRPK1 TADA2A TAF3 TAF8 TANK TBPL2 TP53 TRAF1 TRIM54 TSC22D4 TXNIP UBR5 USHBP1 ZBTB7B ZC3H12A ZNF131 23 interactors: BARD1 CIB1 DYRK2 GSK3B KPNA1 KPNA2 KPNB1 MAPK1 NR1I2 PAIP1 PAIP2 PGR SATB1 SMAD2 TCEA1 TOPBP1 TP53 UBC UBE2A UBE2B UBE2D2 UBE2D3 UBE2L3
Entrez ID 3838 51366
HPRD ID 02818 06436
Ensembl ID ENSG00000182481 ENSG00000104517
Uniprot IDs P52292 Q7Z726 E7EMW7 O95071
PDB IDs 1EFX 1QGK 1QGR 3FEX 3FEY 4E4V 1I2T 2QHO 3PT3
Enriched GO Terms of Interacting Partners?
Tagcloud ?
aggressive  aggressiveness  assembled  attempt  carcinomas  curable  diagnostics  disregarding  eic  emgd  endometrial  entities  figo  immunoreactivity  interplay  introducing  malignancy  mediator  mfe  microarrays  nucleocytoplasmic  precancerous  regimens  surgically  tmas  trp53  tumour  untreatable  uterus 
aberrations  abt  achilles  atm  aurora  birc3  bruton  continues  descending  driver  engagement  exploited  give  heel  ibrutinib  impressive  lethal  mantle  mcl  microenvironment  nevertheless  noncanonical  notch1  recurrently  ribose  sox  traf2  underscored  vulnerabilities 
Tagcloud (Difference) ?
aggressive  aggressiveness  assembled  attempt  carcinomas  curable  diagnostics  disregarding  eic  emgd  endometrial  entities  figo  immunoreactivity  interplay  introducing  malignancy  mediator  mfe  microarrays  nucleocytoplasmic  precancerous  regimens  surgically  tmas  trp53  tumour  untreatable  uterus 
aberrations  abt  achilles  atm  aurora  birc3  bruton  continues  descending  driver  engagement  exploited  give  heel  ibrutinib  impressive  lethal  mantle  mcl  microenvironment  nevertheless  noncanonical  notch1  recurrently  ribose  sox  traf2  underscored  vulnerabilities 
Tagcloud (Intersection) ?